
BeiGene Reports First Patient Dosing in P-III AdvanTIG-302 Trial of Ociperlimab (BGB-A1217) + Tislelizumab (BGB-A317) to Treat Non-Small Cell Lung Cancer
Shots: The first patient has been dosed in global P-III AdvanTIG-302 trial evaluating ociperlimab + tislelizumab in 605 naïve patients with locally advanced, unresectable, or […]